Discovery to preclinical.
Built for gerotherapeutics.
A disciplined engine for identifying, validating, and advancing small-molecule candidates against aging-associated disease biology.
Five-step translational platform
Phenotypic Discovery
Cell-based and high-content systems identify candidates that modulate aging-associated cellular states.
Mechanism Validation
Lead candidates are tested across senescence, inflammatory signaling, cell-death, repair, and stress-response pathways.
Disease Models
Programs advance in models aligned with cognitive decline, cancer persistence, fibrosis, and tissue aging.
Computational Prioritization
AI/ML and computer-aided drug-discovery tools help rank candidates and guide next-generation optimization.
Development Selection
Programs progress based on potency, selectivity, tolerability, IP potential, and translational relevance.
Advance what can become a product
Every program is evaluated through a development lens: biology, therapeutic window, functional endpoint, IP path, and partnership potential.
Does the candidate move aging-relevant biology in a disease-relevant context?
Can the program separate therapeutic activity from unacceptable toxicity?
Can it support a real preclinical milestone and a credible company story?